Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Paul Monk
Study ID
NCT00601926
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    15 mg/kg over 90 minutes every 3 weeks

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well bevacizumab works in treating patients with unresectable or metastatic kidney cancer.

Key Dates

First listed
Jan 28, 2008
Start date
Feb 29, 2008
Status verified
May 2015
Primary completion
Aug 31, 2011
Completion
May 31, 2013

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    15 mg/kg over 90 minutes

Primary Outcome Measure

Progression Free Survival (PFS) When Bevacizumab is Administered to Patients With Unresectable and/or Metastatic Papillary Renal Cell Carcinoma. [ Time Frame: Up to 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Ohio State University Medical CenterColumbusOhio43210-

Find similar trials in Columbus, OH

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Ohio State University Medical Center· Columbus, OH

Related Studies